Prognostic value of Epstein-Barr virus serology in patients with nasopharyngeal carcinoma.
We report the results of a study which examined the prognostic value of Epstein-Barr virus (EBV) serology in patients with nasopharyngeal carcinoma (NPC). Antibody titres to EBV were estimated by indirect immunofluorescence and correlated with the stage of disease. Neither persistent high titres nor falling titres after treatment were found to be reliable indicators of relapse or survival, respectively, in individual patients. By contrast, four-fold rises in titre, particularly of antibodies to the early antigens of the virus were highly significant predictors of relapse. These increases could be seen well in advance of clinical detection of recurrence of the tumour at the primary or metastatic sites.
Regional Virus Laboratory, Royal Victoria Hospital, Belfast, U.K.
D E
DE
Wyatt
D S
DS
Brooker
J H
JH
Connolly
P V
PV
Coyle
D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D002277:Carcinoma / Q000382:microbiology*; D005260:Female; D005455:Fluorescent Antibody Technique; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000382:microbiology*; D011379:Prognosis; D014412:Tumor Virus Infections / Q000175:diagnosis*
D000914:Antibodies, Viral